Toggle navigation
The August 1, 2019, R3 meeting will address two topics: (1) Exporting from China for Research: Biospecimens, DNA and Data and (2) Legal and Ethical Issues in the Enrollment of a Company or Institution’s Own Employees and/or Students in Research Studies.
OptumLabs and MRCT Center announced that two academic institutions were awarded grants to support replication of established clinical trials through the use of electronic health record and claims data.
The MRCT Center, in collaboration with Ropes and Gray, has led an effort to understand the key issues and implications of the GDPR on multi-regional clinical trials, clinical research, and public health.
[CAMBRIDGE, Mass., June 25, 2019]– OptumLabs and the MRCT Center announced that two academic institutions were awarded grants to support replication of established clinical trials through the use of electronic health record (EHR) and claims data, which could help improve clinical trial design and drug development.
As the launch to the project, on May 3, 2019, the MRCT Center invited over 40 representatives from industry, academia, government, and patient advocacy groups to discuss a vision for aglobal, cooperative model of a more proactive, predictive safety surveillance system than exists today.
Ensuring the safety of biological products, drugs, and devices in healthcare is the shared responsibility of regulatory, academic and industry-related stakeholders.
Discussion topics: (1) Exporting from China for Research: Biospecimens, DNA and Data, and (2) Legal and Ethical Issues in the Enrollment of a Company or Institution’s Own Employees and/or Students in Research Studies.
Discussion topic to be determined.
Discussion topics to be determined.
